Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Beijing Puqi Pharmaceutical Technology

Request full access

Develops and issues pharmaceutical products with a focus on innovative medical solutions

ChinaFounded 2016Biotech & Life Sciences

About Beijing Puqi Pharmaceutical Technology

Established in 2016, Beijing Puqi Pharmaceutical Technology, also known as PrimeGene (Beijing), operates as a privately held pharmaceutical company focused on drug discovery and development. The firm is strategically centered on creating new drugs for immune and inflammatory diseases, with a specific emphasis on treatments for skin, ophthalmology, rhinology, and respiratory system conditions. The company's business model encompasses innovative drug research, the development of clinically valuable generic drugs, and pharmaceutical industrialization.

The company's core activities involve the research, development, and commercialization of a pipeline of pharmaceutical products. This drug pipeline includes small molecule drugs targeting immune system diseases, nervous system diseases, neoplasms, infectious diseases, and metabolic disorders. One of its notable drug candidates is Pumecitinib, a JAK tyrosine kinase inhibitor. The company is actively engaged in clinical trials to advance its products toward regulatory approval and market entry. The business generates revenue but is also backed by venture capital, having raised funds to support its R&D and commercialization efforts.

As a privately backed entity, Beijing Puqi Pharmaceutical Technology has secured funding from multiple investors. It has completed several funding rounds, including a Series B round in early 2025, to finance its operations and drug development programs. The company maintains a portfolio of patents related to its discoveries, such as polymorphs of JAK tyrosine kinase inhibitors and their preparation methods. Its client base would primarily consist of patients and healthcare providers upon successful commercialization of its drug candidates, operating within the global biopharmaceutical market. Its main office is located in the Fengtai District of Beijing.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
20.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jan 2025 $41M $165M Beijing Shunxi Equity Investment Fund · E-Town Capital · North Science and Technology Construction ↗
LATE VCOther financing May 2024 $14M $55M Shunxi Private Equity Fund Management ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Beijing Puqi Pharmaceutical Technology website traffic

Latest recorded traffic for Beijing Puqi Pharmaceutical Technology is 160 monthly website visits, up 128.6% over the last three months.

Latest monthly visits160 3-month web change+128.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Beijing Puqi Pharmaceutical Technology in its local ecosystem

Live from Dealroom

The Beijing Puqi Pharmaceutical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Beijing Shunxi Equity Investment Fund
  • E-Town Capital
  • North Science and Technology Construction

Series B and later1 investor entered at this stage

  • Shunxi Private Equity Fund Management
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Beijing Puqi Pharmaceutical Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Beijing Puqi Pharmaceutical Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.